Quintiles Invites Former Google Health Users to Join MediGuard.org
With the ringing in of the new year, patients and family members of the now bygone Google Health can still find a well established, online option for managing personal healthcare information in Quintiles’ MediGuard.org service.
Supported by global biopharmaceutical services provider, Quintiles, MediGuard.org has attracted more than 2.5 million patients since its inception in 2007 by providing free medication monitoring services, and is extending an open invitation to former Google Health users.
“We are extending an open invitation to all patients whose service with Google Health has ended,” said David Coman, senior vice president at Quintiles and head of its new Digital Patient Unit. “MediGuard is a free, easy-to-use service that is very effective in monitoring medications for patient safety. With that dedicated purpose, we’ve built a community on a scale that Google seemed to feel was not going to be possible for its health platform.”
Google Health was discontinued on January 1, 2012. When announcing the closure last June, Google explained that the service “didn’t scale as well as we had hoped.”
Coman added: “Google Health was a brilliant concept, but in order for online patient services to work, there must be a clear benefit to patients who enroll in them. MediGuard’s contribution is an easy-to-use service for patients to support a healthy lifestyle, many of whom are taking multiple medications for various conditions.”
According to Quintiles, its campaign to convert Google Health users is comprised of traditional non-paid media outlets, with a look toward using search engine optimization and search engine marketing as additional options.
Patients who register with MediGuard can store information about their own use of medicines, protected by a robust privacy policy and a secure platform. This allows the service to screen for possible dangerous drug interactions and safety alerts for the patient’s drugs while also providing feedback from fellow patients on side effects and other important information.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
